Analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Mawson Infrastructure Group in a note issued to investors on Tuesday, November 26th. HC Wainwright analyst K. Dede now ...

Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for Oruka Therapeutics in a research report issued ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of SoundHound AI ...

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.

On Wednesday, H.C. Wainwright reaffirmed its Buy rating and $40.00 stock price target for GH Research PLC (NASDAQ:GHRS), following the company's third-quarter financial results and corporate update.

On Tuesday, H.C. Wainwright increased its price target for Bitdeer Technologies Group (NASDAQ: BTDR) to $18.00, up from the previous $17.00, while maintaining a Buy rating on the stock.